Skip to main content
. 2016 Jan 29;78(4):657–668. doi: 10.1292/jvms.15-0387

Fig. 3.

Fig. 3.

Effects of supplementation of PGE2 on enhancement of growth inhibitory activity of doxorubicin caused by deracoxib in CMT-U27 cells. Cells were treated with or without deracoxib (50-250 µM) in the absence or presence of PGE2 (1 or 5 µM) and 0.9 µM doxorubicin (A) or 0.09 µM doxorubicin (B) alone or in combination for 72 hr before determination of cell viability by MTT assay. DOX, doxorubicin; DER, deracoxib.